Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNYBiotechnology
-$6.27 today
- Market cap
- $20.01B
- Beta
- 0.27
- P/E (TTM)
- 63.6
- EPS (TTM)
- $4.34
Volume 2.52M
Average 1.11M
ALNY Total Current Liabilities
All obligations due within one year.
Alnylam Pharmaceuticals, Inc.NASDAQ: ALNY
Total Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total current liabilities rises 16.3% from a year ago
Total current liabilities stood at $1.51B at the end of Q2 FY2026, up 16.3% from a year earlier and up 12.1% from the prior quarter. Over 3 fiscal years it compounded at +24.1% a year.
Context
- Total current liabilities amounted to 27.2% of total assets at the end of Q2 FY2026, down 1.3 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +16.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.47B USD
- Year-over-year change
- +23.6%
- 4-year CAGR
- +20.5%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.47B | +23.6% |
| FY2024 | 2024-12-31 | 1.19B | +22.6% |
| FY2023 | 2023-12-31 | 967.79M | +26.0% |
| FY2022 | 2022-12-31 | 767.92M | +10.4% |
| FY2021 | 2021-12-31 | 695.71M | — |
Total Current Liabilities vs competitors
How ALNY compares with its peers on the latest reported figures
- ALNY's Jun 2026 total current liabilities of $1.51B is the highest of the 6 companies compared; the peer median is $76.45M.
- Its year-over-year change of +16.3% is the 2nd highest of 6, against a peer median of -43.0%.
- Total current liabilities amounts to 27.2% of total assets for ALNY, versus a peer median of 10.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.51B | +16.3% | +24.1% | 27.2% | |
| Sep 2026 | $435.29M | -51.8% | +35.9% | 14.9% | |
| Sep 2026 | $311.34M | +59.3% | +43.5% | 17.9% | |
| Mar 2026 | $76.45M | -32.1% | -6.4% | 10.1% | |
| Mar 2026 | $49.83M | -43.0% | +10.0% | 8.5% | |
| Mar 2026 | $10.46M | -45.7% | -14.7% | 9.1% | |
| Peer median (excluding ALNY) | $76.45M | -43.0% | +10.0% | 10.1% | |
Competitors are the stored peer set for ALNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 819.98M | 866.39M | 812.69M | 966.43M | 1.66B |
| Short-term Investments | 1.62B | 1.33B | 1.63B | 1.73B | 1.25B |
| Net Receivables | 198.57M | 237.96M | 327.79M | 405.31M | 777.57M |
| Inventory | 86.36M | 128.96M | 89.15M | 78.51M | 82.72M |
| Other Current Assets | 0 | 132.92M | 126.38M | 116.96M | 281.89M |
| Total Current Assets | 2.81B | 2.69B | 2.98B | 3.3B | 4.05B |
| Property, Plant & Equipment (Net) | 733.63M | 738.63M | 725.79M | 693.93M | 708.06M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 10.1M | 116.86M | 125.98M |
| Other Non-current Assets | 101.1M | 115.48M | 111.29M | 133.9M | 81.63M |
| Total Non-current Assets | 834.73M | 854.11M | 847.18M | 944.7M | 915.67M |
| Total Assets | 3.64B | 3.55B | 3.83B | 4.24B | 4.97B |
| Account Payables | 73.43M | 98.09M | 55.52M | 88.42M | 115.72M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 149.48M | 42.11M | 102.75M | 55.48M | 4.85M |
| Other Current Liabilities | 130.66M | 170.98M | 177.16M | 421.2M | 477.27M |
| Total Current Liabilities | 695.71M | 767.92M | 967.79M | 1.19B | 1.47B |
| Long-term Debt | 675.7M | 1.02B | 1.02B | 1.02B | 1.01B |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 152.36M | 193.79M | 188.18M | 0 | 0 |
| Other Non-current Liabilities | 1.25B | 1.46B | 1.63B | 1.73B | 1.48B |
| Total Non-current Liabilities | 2.36B | 2.94B | 3.08B | 2.99B | 2.71B |
| Total Liabilities | 3.06B | 3.7B | 4.05B | 4.17B | 4.18B |
| Common Stock | 1.2M | 1.24M | 1.26M | 1.29M | 1.32M |
| Retained Earnings | (5.44B) | (6.57B) | (7.01B) | (7.29B) | (6.7B) |
| Accumulated OCI | (33.26M) | (44.65M) | (23.38M) | (34.52M) | (20.1M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 588.2M | (158.22M) | (220.64M) | 67.09M | 789.18M |
| Total Debt | 997.59M | 1.32B | 1.31B | 1.3B | 1.28B |
| Net Debt | 177.62M | 453.85M | 492.7M | 329.62M | (378.86M) |
Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
Intrinsic Alpha fair value
Locked
Current Price
$149.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.